India’s Cumulative COVID-19 Vaccination Coverage crosses 66 Cr landmark

New Delhi : In a significant achievement, India’s cumulative vaccination coverage crossed 66 Crore landmark yesterday. With the administration of 81,09,244vaccine doses in the last 24 hours, India’s COVID-19 vaccination coverage has surpassed the cumulative figure of 66.30Cr (66,30,37,334) as per provisional reports till 7 am today. This has been achieved through 69,60,983sessions.

The break-up of the cumulative figureas per the provisional report till 7 am today include:

 

 

HCWs

1st Dose 1,03,59,391
2nd Dose 84,14,897
 

FLWs

1st Dose 1,83,25,922
2nd Dose 1,33,20,833
 

Age Group 18-44 years

1st Dose 25,97,17,695
2nd Dose 2,98,87,208
 

Age Group 45-59 years

1st Dose 13,33,18,523
2nd Dose 5,59,07,199
 

Over 60 years

1st Dose 8,80,78,095
2nd Dose 4,57,07,571
Total 66,30,37,334

 

The Union Government is committed to accelerating the pace and expanding the scope of COVID-19 vaccination throughout the country.

The recovery of35,181 patients in the last 24 hours has increased the cumulative tally of recovered patients (since the beginning of the pandemic) to 3,20,28,825.

Consequently, India’s recovery rate stands at 97.48%.

Sustained and collaborative efforts by the Centre and the States/UTs continue the trend of less than 50,000 Daily New Cases that is being reported for 67 consecutive days now.

47,092 new cases were reported in the last 24 hours.

The Active Caseload is presently3,89,583. Active cases presently constitute 1.19% of the country’s total Positive Cases.

The testing capacity across the country continues to be expanded. The last 24 hours saw a total of 16,84,441tests being conducted. India has so far conducted over 52.48 Cr (52,48,68,734) cumulative tests.

While testing capacity has been enhanced across the country, Weekly Positivity Rate at 2.62% remains less than 3% for the last 69 days now. The Daily Positivity rate stands at 2.80%. The daily Positivity rate has remained below 5% for 87 consecutive days now.

 

Comments are closed.